Omini

Omini, based in France, is a provider of innovative sensor-based technology for near-patient and self-testing of blood samples, primarily focused on chronic disease management. Founded in 2019 in Saint-Mande, France, Omini specializes in advanced blood testing solutions. The company has undergone significant developments since its inception, raising EUR 884,812 in venture funding from Entrepreneur First on July 6, 2021. Joanne Kanaan serves as the CEO, while the company was co-founded by Anna Shirinskaya and Joanne Kanaan.

Omini has engaged in one deal to date, raising a total of EUR 884,812, representing its complete funding history as of the latest round. Omini specializes in innovative, sensor-based technology designed for near-patient and self-testing of blood samples, catering primarily to patients suffering from chronic diseases. The core offering consists of multi-sensing blood testing strips, a portable connected reader, and an application that facilitates the transmission of clinical and biological data. This integrated solution promotes precision medicine and emphasizes a shift towards preventive care.

By enabling decentralized blood testing, Omini aims to enhance patient management and engagement through real-time data sharing between patients and healthcare providers. The technology has been developed for markets in North America and Europe, targeting healthcare facilities, clinics, and directly serving patients who require regular monitoring of their health conditions. Omini generates revenue through a structured business model that encompasses direct sales of its testing technology to healthcare providers and patients. The company engages in subscription-based services for ongoing access to its application and data analysis features, ensuring continual support and updates.

Additionally, Omini forms strategic partnerships with healthcare organizations to expand its reach and enhance service offerings. These partnerships involve bulk sales of testing kits and subscription services, fostering a consistent revenue stream. The firm’s flagship products, including its patented blood testing strips and connected reader, are positioned to meet the growing demand for accessible healthcare solutions, contributing to the overall financial performance of the company. Omini plans to leverage its recent funding of EUR 884,812 to enhance its product line and penetrate new markets.

The company is developing upcoming products that will extend its sensor-based technology to additional healthcare applications. Specific geographic regions targeted for expansion include other European countries and North America, with plans to establish a presence by 2023. The funding will facilitate the design and launch of new products while supporting marketing efforts to ensure successful market entry.